Your browser is no longer supported

For the best possible experience using our website we recommend you upgrade to a newer version or another browser.

Your browser appears to have cookies disabled. For the best experience of this website, please enable cookies in your browser

We'll assume we have your consent to use cookies, for example so you won't need to log in each time you visit our site.
Learn more


  • Comment

Information about simvastatin, a lipid-lowering medication used to reduce the risk of heart disease.

Generic and proprietary names

- Simvastatin/Zocor.


- Inhibits HMG-CoA reductase enzyme, which reduces cholesterol synthesis.


- Statin.

- Antilipidemic.

- HMG-CoA reductase inhibitor.


- Primary hypercholesterolaemia.

- Heterozygous familial hypercholesterolaemia.

- Homozygous familial hypercholesterolaemia or combined hyperlipidaemia in patients who have not responded enough to dietary changes.

- Prevention of coronary events.

- To slow progress of coronary atherosclerosis in patients with coronary heart disease.


- Hypersensitivity.

- Pregnancy.

- Lactation.

- Active liver disease.


- Past liver disease.

- Severe acute infection.

- Alcoholism.

- Trauma.

- Severe metabolic disorders.

- Hypotension.

- Uncontrolled seizure disorders.

- Electrolyte imbalances.

Common side-effects

- Rash.

- Pruritis.

- Alopecia.

- Nausea/vomiting.

- Bowel problems.

- Abdominal pain.

- Liver dysfunction.

- Lens opacities.

- Myalgia.

- Rhabdomyolysis.

- Headache.

- Peripheral neuropathy.

- Anaemia.

- Dizziness.

- Parasthesia.

- Peripheral neuropathy.

- Hepatitis.

- Jaundice.

- Pancreatitis.

- Myopathy.

Rare side-effects

- Reversible myositis.

- Hepatitis.

- Angiodema.

- Anaphylaxis.


- Increased effects of warfarin.

- Digoxin, ciclosporin, amiodarone, verapamil, diltiazem, fibrates, nicotinic acid, erythromycin, clarithromycin, macrolide antibiotics, azole antifungals, immunosuppressants, protease inhibitors, grapefruit juice.


- Tablet.

Nursing considerations

- Carry out lipid profile.

- Assess cholesterol at six weeks.

- Perform liver function tests in first year of treatment.

- In the case of rhabdomyolysis with increased muscle tenderness and creatine phosphokinase, therapy should be discontinued.

- Renal tests for patients with impaired renal function.

- Eye tests before treatment, after one month, then annually.

Patient teaching

- Advise patients that blood and eye tests will be necessary throughout treatment.

- Blurred vision, severe gastrointestinal problems, dizziness or headaches must be reported.

- A low cholesterol diet and exercise programme are recommended.

- Medication should be stored in a closed container in a cool, dry, dark place, out of the reach of children.

- Nurses should refer to manufacturer’s summary of product characteristics and to appropriate local guidelines.

  • Comment

Have your say

You must sign in to make a comment

Please remember that the submission of any material is governed by our Terms and Conditions and by submitting material you confirm your agreement to these Terms and Conditions. Links may be included in your comments but HTML is not permitted.